Syngene International reports Q2 FY26 consolidated PAT at Rs. 67.1 Cr

Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025

Syngene International expands capabilities with new bioconjugation suite in Bengaluru

Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services

Syngene International invests in peptide laboratory in Bengaluru

Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services

Syngene International appoints Gaurav Kushwaha as CTO

Kushwaha previously served as Chief Digital & Information Officer at Jubilant Ingrevia Limited

Syngene International posts Q4 FY25 consolidated profit at Rs. 183.3 Cr

Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time

Peter Bains appointed MD & CEO of Syngene International

He has global experience in strategic and operational leadership levels with an extensive track record of leadership and success in building companies, businesses, teams, and brands for over 30 years

Briefs: Syngene International and Cipla

Cipla Limited has received final approval from the USFDA for the New Drug Application submitted for ‘Nilotinib Capsules 50, 150 and 200 mg’

Syngene International posts Q2 FY25 consolidated PAT at Rs. 106.1 Cr

Syngene International reports Q4 FY24 consolidated PAT at Rs. 188.6 Cr

Syngene International has reported total income of Rs. 933 crores during the period ended March 31, 2024

ERS Genomics completes licensing agreement with Syngene International

Syngene gains access to ERS Genomics' foundational CRISPR/Cas9 patent portfolio, ushering in a new era of technical innovation in India for its global partners